Rigel has exclusive commercialization license agreements with Medison to commercialize TAVALISSE (fostamatinib disodium hexahydrate) in all potential indications in Canada and Israel.
TAVALISSE launched in Canada in December 2020 for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments. It is the first and only spleen tyrosine kinase (SYK) inhibitor approved in Canada for this indication.
In November 2022, TAVALISSE launched in Israel for the treatment of chronic ITP in adult patients who are refractory to other treatments.
Rigel received an upfront payment, which included an advanced royalty payment, is eligible for regulatory and commercial milestone payments, and receives tiered royalty payments on net sales of TAVALISSE in the territory.